Myths About Risk of Familial Breast Cancer

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

As someone who disliked pink for years, it has grown on me over time, especially after having breast cancer.

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

When I underwent surgery for breast cancer, reconstruction was highly recommended, but I decided to remain flat — a decision I think about sometimes.

For some patients with breast cancer, ctDNA may have the potential to predict disease relapse after they have undergone surgery and chemotherapy.